Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicyluric Acid SCHEMBL2496831 | 0.84 | EGLN1 (0.39) | ALDH1A1KDM4EHPGDMAPTTSHR | |
| SCHEMBL6363070 | 0.81 | ALDH1A1 (0.54) | DAOALDH1A1KDM4EHPGDSMN1; SMN2 | |
| SCHEMBL28961750 | 0.72 | ADORA2B (0.57) | DAOALDH1A1KDM4ESMN1; SMN2MAPT | |
| SCHEMBL11570798 | 0.72 | GDA (0.40) | ALDH1A1HPGDALOX15HSD17B10 | |
| SCHEMBL28985259 | 0.71 | PKM (0.49) | KDM4EMEN1LMNAKMT2ACYP2D6 | |
| SCHEMBL8624436 | 0.69 | MPO (0.33) | MPODAOALDH1A1KDM4EHPGD | |
| SCHEMBL923439 | 0.69 | ADORA2A (0.47) | ALDH1A1HPGDSMN1; SMN2MAPTTSHR | |
| SCHEMBL29086727 | 0.67 | ADORA2A (0.46) | ALDH1A1HPGDSMN1; SMN2MAPTTSHR | |
| SCHEMBL7519792 | 0.65 | HSD17B10 (0.50) | ALDH1A1KDM4EHPGDMAPTTSHR | |
| SCHEMBL14882309 | 0.65 | ADORA2B (0.51) | ALDH1A1KDM4EMEN1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| EP-3383177-B1 | COMPOSITION FOR CROP CARE AND PROTECTION | ALPHA BIOPESTICIDES LTD (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260097105-A1 | SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2026-04-09 | — | — | US | claimed |
| US-20250258146-A1 | QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP | HUMAN METABOLOMICS INSTITUTE INC. (CN) | 2025-08-14 | — | — | US | claimed |
| US-20250258159-A1 | DEVICE, METHOD AND SYSTEM FOR MONITORING IMMUNE SYSTEM RESPONSE | Olaris, Inc. | 2025-08-14 | — | — | US | claimed |
| US-20250152609-A1 | SALICYLIC ACID COMPOSITIONS AND USES THEREOF | PHARMALP SA (CH) | 2025-05-15 | — | — | US | claimed |
| WO-2025072741-A1 | PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-04-03 | — | — | WO | claimed |
| EP-4482580-A1 | SALICYLIC ACID COMPOSITIONS AND USES THEREOF | PharmAlp SA (CH) | 2025-01-01 | — | — | EP | claimed |
| WO-2024072958-A1 | SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2023161247-A1 | SALICYLIC ACID COMPOSITIONS AND USES THEREOF | PHARMALP SA (CH) | 2023-08-31 | — | — | WO | claimed |
| EP-0711774-B1 | Crystalline cephem-addition salts and process for their preparation | AVENTIS PHARMA GMBH (DE) | 2002-02-13 | — | — | EP | claimed |
| US-5747484-A | BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-05 | — | — | US | claimed |
| CN-1129220-A | Novel crystalline cephem acid addition salts and processes for their preparation | HOECHST AG (DE) | 1996-08-21 | — | — | CN | claimed |
| EP-0225189-A2 | Targeted enteral delivery system | R.P. SCHERER CORPORATION (US) | 1987-06-10 | — | — | EP | claimed |
| EP-0031561-B1 | A RECTALLY ADMINISTERED SUPPOSITORY COMPRISING A DRUG AND AN ADJUVANT | MERCK & CO. INC. (US) | 1985-04-10 | — | — | EP | claimed |
| US-4406896-A | ANTIBIOTICS, ACIDS, HYDROXY | MERCK & CO., INC. (US) | 1983-09-27 | — | — | US | claimed |
| EP-0036534-A1 | An orally administrable drug form comprising a beta-lactam antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-30 | — | — | EP | claimed |
| EP-0036145-A1 | An orally administered drug form comprising a polar bioactive agent and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-23 | — | — | EP | claimed |
| EP-0035770-A2 | An orally administered drug form comprising a glycosidic antibiotic and an adjuvant | INTERx RESEARCH CORPORATION (US) | 1981-09-16 | — | — | EP | claimed |
| EP-0031561-A2 | A rectally administered suppository comprising a drug and an adjuvant | MERCK & CO. INC. (US) | 1981-07-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097105-A1 | SYSTEMS, FORMULATIONS AND METHODS FOR GENERATING UNIVERSAL PEPTIDE/MHC COMPLEXES WITH ENGINEERED DISULFIDE CONNECTING THE HEAVY AND LIGHT CHAINS | HLA-DRB1, MICA, FTH1 | MPO 1260/4885DAO 2495/4885ALDH1A1 2649/4885 |
| US-20250152609-A1 | SALICYLIC ACID COMPOSITIONS AND USES THEREOF | UROD, BPHL, SYMPK | MPO 819/4885DAO 248/4885ALDH1A1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.